12399456https://www.upal.com.my/zh/feeds/jobFeedKwongwahArray ( [0] => HTTP/1.1 200 OK [1] => Date: Sun, 11 Jan 2026 10:00:49 GMT [2] => Content-Type: text/xml; charset=utf-8 [3] => Connection: close [4] => Cache-Control: no-cache, private [5] => Cache-Control: no-cache, no-store, must-revalidate [6] => Set-Cookie: UpalLiveSession=eyJpdiI6InVcL2ZpdFI2RTlvVWRKUDJMenJMMUpnPT0iLCJ2YWx1ZSI6IlNNSTRWVVdPSFVxY3NYY0dLN2x6b3kyQ0lFQWhGSDVzQmIxNXpGeXhRV2NtTkRoVmxaRkwzOWZrMXJJRnh2Y043WXM1Z2MraXBcL2hDR2hUYm44cHF4UT09IiwibWFjIjoiODFlMGY0NDE3NzJlNDA1N2Q0NDg2OTQ0Njk4OTk5YTIwNDgyZDBiYzFjNDJjYmNjYzFhYmJhYmYwYTBiMzc0MCJ9; expires=Wed, 10-Jan-2029 10:00:49 GMT; Max-Age=94608000; path=/; HttpOnly [7] => x-frame-options: SAMEORIGIN [8] => x-content-type-options: nosniff [9] => x-xss-protection: 1; mode=block [10] => referrer-policy: strict-origin-when-cross-origin [11] => permissions-policy: geolocation=(), microphone=(), camera=() [12] => content-security-policy: default-src * 'unsafe-inline' 'unsafe-eval' data: blob:; script-src * 'unsafe-inline' 'unsafe-eval' data: blob:; style-src * 'unsafe-inline' data:; img-src * data: blob:; font-src * data:; connect-src *; frame-src *; object-src *; media-src *; child-src *; [13] => Server: cloudflare [14] => x-robots-tag: noindex, nofollow, nosnippet, noarchive [15] => strict-transport-security: max-age=31536000; includeSubDomains; preload [16] => expires: Mon, 12 Jan 2026 10:00:48 GMT [17] => vary: Accept-Encoding [18] => Report-To: {"group":"cf-nel","max_age":604800,"endpoints":[{"url":"https://a.nel.cloudflare.com/report/v4?s=lBza9iBZ7dP8ks3rgrU%2Fyhty%2BSkaWLPTnKoUWSOE2Z4ZMfLFTG8JNBezTXuvMlGRc4pf2Jb1c91ovLzNV2fr7C9Sk%2F%2BXSAIpTR8cuhf8gQ%3D%3D"}]} [19] => cf-cache-status: DYNAMIC [20] => Nel: {"report_to":"cf-nel","success_fraction":0.0,"max_age":604800} [21] => Speculation-Rules: "/cdn-cgi/speculation" [22] => Server-Timing: cfCacheStatus;desc="DYNAMIC" [23] => Server-Timing: cfEdge;dur=3,cfOrigin;dur=809 [24] => CF-RAY: 9bc391b69d5f1268-LAX [25] => alt-svc: h3=":443"; ma=86400 ) 789

中国淅江省多个医疗机构与企业合作研发的第一批疫苗已经产生抗体，并进入动物实验阶段。

这是该省于周六（22日）举行的第27场新型冠状病毒肺炎疫情防控工作新闻发布会上，宣布这项消息。

省卫生健康委副主任孙黎明表示，该省疫苗研发方面开展了多种技术研发路线，并持续推进病毒分离、推进动物实验等关键环节，目前取得了良好进展。首批疫苗已产生抗体，重组腺病毒载体疫苗，开始进行重组病毒的培养，近期将开展动物实验。快速检测产品亦正在积极争取进入国家药监局应急审批通道。

孙又提到，目前全省除没有病例的11个县市区之外，有75个县市区连续5天没有新增确诊病例；有20个县市区降低了风险等级。

---

// // // //